Cargando…

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, espec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clark, Curtis A., Yang, Eddy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497895/ https://www.ncbi.nlm.nih.gov/pubmed/34631532 http://dx.doi.org/10.3389/fonc.2021.703802

Ejemplares similares

Understanding and harnessing triple-negative breast cancer-related microbiota in oncology
por: Devoy, Ciaran, et al.
Publicado: (2022)

Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
por: Manouchehri, Jasmine M., et al.
Publicado: (2022)

Harnessing DNA Double-Strand Break Repair for Cancer Treatment
por: Trenner, Anika, et al.
Publicado: (2019)

Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
por: Rajani, Karishma R., et al.
Publicado: (2019)

Exploiting DNA repair defects in triple negative breast cancer to improve cell killing
por: Lee, Kevin J., et al.
Publicado: (2020)

Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2019)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy
por: Deng, Xiyun, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
por: Naik, Adviti, et al.
Publicado: (2020)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Ren, Xin-yu, et al.
Publicado: (2021)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
por: Cao, Xi, et al.
Publicado: (2021)

Propofol Inhibits Proliferation and Augments the Anti-Tumor Effect of Doxorubicin and Paclitaxel Partly Through Promoting Ferroptosis in Triple-Negative Breast Cancer Cells
por: Sun, Chen, et al.
Publicado: (2022)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Venetis, Konstantinos, et al.
Publicado: (2021)

Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway
por: Wang, Kai-nan, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies
por: Tse, Ka Yu, et al.
Publicado: (2022)

Harnessing immunomodulation during DNA damage in Ewing sarcoma
por: Daley, Jessica D., et al.
Publicado: (2022)

Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors
por: Clark, Curtis A., et al.
Publicado: (2022)

Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC)
por: Kulasinghe, Arutha, et al.
Publicado: (2022)

Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer
por: Wang, Xin-Hua, et al.
Publicado: (2022)

Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors
por: Qin, Ruoyan, et al.
Publicado: (2023)

Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer
por: Chen, Yi-Yu, et al.
Publicado: (2020)

Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway
por: Lu, Xing, et al.
Publicado: (2023)

Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy
por: Haritha, Nair Hariprasad, et al.
Publicado: (2021)

Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity
por: Schirrmacher, Volker, et al.
Publicado: (2014)

Harnessing the immune system in the treatment of cutaneous T cell lymphomas
por: Fay, Christopher J., et al.
Publicado: (2023)

DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
por: Sheng, Xianneng, et al.
Publicado: (2021)

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer
por: Mast, Jesse M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jhp0j3pl4mscfioaou8hk3le61